SeQuent Scientific is currently trading at Rs. 127.25, up by 0.30 points or 0.24% from its previous closing of Rs. 126.95 on the BSE.
The scrip opened at Rs. 131.80 and has touched a high and low of Rs. 131.80 and Rs. 125.05 respectively. So far 1,675 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 257.00 on 20-Dec-2012 and a 52 week low of Rs. 101.00 on 27-Jul-2012.
Last one week high and low of the scrip stood at Rs. 131.75 and Rs. 106.00 respectively. The current market cap of the company is Rs. 305 crore.
The promoters holding in the company stood at 60.47% while Institutions and Non-Institutions held 0.17% and 39.36% respectively.
SeQuent Scientific has signed a Letter of Intent (LOI) with Shasun Pharmaceuticals to form a joint venture company (JVC) to develop, manufacture and sell veterinary products inclusive of both API (Active Pharmaceutical Ingredients) and formulations in the global market. Together, SeQuent and Shasun aim to quickly and effectively offer a range of veterinary products globally through the JVC.
In terms of the arrangement proposed in the LOI, SeQuent & Shasun will set up a JVC, into which contributions will be made by both companies by way of transfer of identified assets, contracts and licenses. SeQuent will own 73% of the JVC and Shasun will own the remaining 27% ownership in the JVC. The creation of the JVC is subject to the requisite corporate and statutory approvals, as may be applicable and is expected to operate from Q1 2014. On successful completion of this arrangement, the JVC will emerge as India’s leading provider of animal health solutions.
The joint venture will benefit from SeQuent’s strong expertise in the development and commercialization of animal health care products as well as SeQuent’s strong sales network. SeQuent’s capabilities are complementary to Shaun’s global expertise in the research, development and manufacture of pharmaceutical ingredients. This joint venture brings the companies one step closer to providing highest quality veterinary products and supports their strategy to enter key, fast- growing markets.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: